Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant Gliomas

Clinical trial NCT00939991 · COMPLETED

Trial details

NCT number: NCT00939991
Sponsor: Katy Peters
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Brain Tumor Glioblastoma

Start date: 2009-10-01
Primary completion: 2012-01-01
Enrollment: 48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.